Market Overview

Sell-Side Roundup: What's Next For For Applied Genetic After 50% Plunge?

Share:
Sell-Side Roundup: What's Next For For Applied Genetic After 50% Plunge?

Applied Genetic Technologies Corp (NASDAQ: AGTC), a biotech focused on adeno-associated virus-based gene therapies for the treatment of rare diseases, reported disappointing results from an X-linked retinoschisis clinical study.

The company also confirmed Biogen Inc (NASDAQ: BIIB) terminated its partnership effective March 8.

The Analysts

H.C. Wainwright & Co's Joseph Pantginis maintains a Buy rating on Applied Genetic Technologies' stock with a price target lowered from $8 to $5.75.

Wedbush's David Nierengarten maintains at Outperform, price target lowered from $12 to $11.

BMO Capital Markets' Matthew Luchini downgrades from Outperform to Market Perform, price target lowered from $13 to $5.

HC Wainwright: Here's What Happened

Applied Genetic's XLRS clinical study consisted of 27 patients. The 13 who received a high dose showed no improvements, with just two patients showing improvements in one of the four endpoints, OCT, Pantginis said in a research report. Zero pediatric patients at the middose showed efficacy at any endpoint, he said. 

Given the disappointing announcement, investor confidence has taken a hit and the company is now entering a "show me stage," the analyst said.

The bullish case for the stock can still be made, as there are some differentiating factors between the reported XLRS programs and XLRP programs, Pantginis said:

  • XLRS included intravitreal injections and was dosed into a highly heterogeneous population.
  • The XLRP programs are dosed in subretinal fashion.

Wedbush: Silver Lining In Biogen Announcement

Applied Genetic's Biogen termination announcement has a "silver lining," as the company now has full rights to the XLRP gene therapy program, which is seen as a primary value driver, Nierengarten said in a research report.

Biogen previously controlled worldwide rights to the XLRS program and Applied Genetics merely received a low-teens royalty payment, the analyst said. 

Applied Genetic is now positioned to benefit from more upside in the XLRP program, which boasts multiple advantages over XLRS, Nierengarten said:

  • A larger market.
  • Better-defined biology through validated higher order animal models.
  • Clinical POC established by other sponsors.
  • Superior benefits of subretinal delivery.

On the flipside, Applied Genetics will likely need incremental financing to proceed, but there is nevertheless a "positive path forward" with its XLRP opportunity, according to Wedbush. 

Related Link: Wells Fargo Bullish On Applied Genetic Technologies Ahead Of Program Update

BMO: Negative Signal From Biogen

Although the return of full rights related to XLRP from Biogen is a positive development for Applied Genetic, the fact that Biogen decided to return rights ahead of proof-of-concept data — which is expected in the third quarter of 2019 — is a "negative signal," Luchini said in the downgrade note.

This also implies incremental risk to the company's success in XLRP, for which BMO lowered its probability of success from 15 percent to 10 percent, the analyst said. 

Price Action

Shares of Applied Genetics hit a new 52-week low of $3.32 Thursday and were down 47.56 percent at $3.44 at the time of publication. 

Related Link: The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen

Latest Ratings for AGTC

DateFirmActionFromTo
Sep 2019MaintainsOutperform
Sep 2019UpgradesMarket PerformOutperform
Sep 2019Initiates Coverage OnBuy

View More Analyst Ratings for AGTC
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Biotech Downgrades Price Target Reiteration Analyst Ratings General Best of Benzinga

 

Related Articles (BIIB + AGTC)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
CMGCredit SuisseMaintains930.0
HASSunTrust Robinson HumphreyMaintains102.0
MCDCredit SuisseMaintains230.0
TWTRBMO CapitalMaintains45.0
SHWCredit SuisseMaintains610.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

These Were The 10 Most Actively Traded OTCQX and OTCQB Securities In November

Under Armour Slides After Five-Year Plan Fails To Excite Investors